Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft

Fusser, Markus; Øverbye, Anders; Pandya, Abhilash D.; Mørch, Ýrr; Borgos, Sven Even F.; Kildal, Wanja; Snipstad, Sofie; Sulheim, Einar; Fleten, Karianne G.; Askautrud, Hanne A.; Engebraaten, Olav; Flatmark, Kjersti; Iversen, Tore Geir; Sandvig, Kirsten; Skotland, Tore; Mælandsmo, Gunhild Mari

doi:10.1016/j.jconrel.2018.11.029

Cited by 44 publications

(47 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Free cabazitaxel was somewhat more efficient than the encapsulated cabazitaxel (NP-cab) in terms of the larger number of survivors, although the difference in tumor growth was not significant. This contrasts with the previously observed efficacy for the same type of NPs in a breast cancer model (Fusser et al 2019), where the NP-cab group performed better than the free cab group. This difference is likely owing to differences in the microenvironments of the two tumor models.…”

Section: Article In Presscontrasting

confidence: 99%

“…It is effective against cancers with resistance to other taxanes, and is approved for treatment of metastatic prostate cancer. The poly(alkyl cyanoacrylate) (PACA) NPs have been characterized with respect to cellular uptake, degradation and toxicity (Sulheim et al 2016(Sulheim et al , 2017, surface PEGylation (A slund et al 2017b), stability of fluorescent payloads (Snipstad et al 2014(Snipstad et al , 2017a, in vivo circulation time and biodistribution (A slund et al 2017b;Snipstad et al 2017b) and efficacy (Fusser et al 2019). NPMBs have also been used to enhance the delivery and therapeutic effect of NPs in solid tumors (Snipstad et al 2017b;Yemane et al 2019) and across the bloodÀbrain barrier Baghirov et al 2018;Sulheim et al 2019).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sonopermeation Enhances Uptake and Therapeutic Effect of Free and Encapsulated Cabazitaxel

Snipstad

Mørch

Sulheim

et al. 2021

Ultrasound in Medicine & Biology

Self Cite

View full text Add to dashboard Cite

Delivery of drugs and nanomedicines to tumors is often heterogeneous and insufficient and, thus, of limited efficacy. Microbubbles in combination with ultrasound have been found to improve delivery to tumors, enhancing accumulation and penetration. We used a subcutaneous prostate cancer xenograft model in mice to investigate the effect of free and nanoparticle-encapsulated cabazitaxel in combination with ultrasound and microbubbles with a lipid shell or a shell of nanoparticles. Sonopermeation reduced tumor growth and prolonged survival (26%À100%), whether the free drug was co-injected with lipid-shelled microbubbles or the nanoformulation was co-injected with lipid-shelled or nanoparticle-shelled microbubbles. Coherently with the improved therapeutic response, we found enhanced uptake of nanoparticles directly after ultrasound treatment that lasted several weeks (2.3 £ À15.8 £ increase). Neither cavitation dose nor total accumulation of nanoparticles could explain the variation within treatment groups, emphasizing the need for a better understanding of the tumor biology and mechanisms involved in ultrasound-mediated treatment.

show abstract

Section: Article In Presscontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sonopermeation Enhances Uptake and Therapeutic Effect of Free and Encapsulated Cabazitaxel

Snipstad

Mørch

Sulheim

et al. 2021

Ultrasound in Medicine & Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…For small‐molecule drugs, highly efficient encapsulation in polymeric nanoparticles can be achieved, e.g . through miniemulsion‐based synthesis, followed by in situ polymerisation (Fusser et al, 2019). However, due to their negative charge, anionic ONs cannot be encapsulated using this approach.…”

Section: Introductionmentioning

confidence: 99%

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

et al. 2021

View full text Add to dashboard Cite

Nucleic acid‐based therapeutics that regulate gene expression have been developed towards clinical use at a steady pace for several decades, but in recent years the field has been accelerating. To date, there are 11 marketed products based on antisense oligonucleotides, aptamers and small interfering RNAs, and many others are in the pipeline for both academia and industry. A major technology trigger for this development has been progress in oligonucleotide chemistry to improve the drug properties and reduce cost of goods, but the main hurdle for the application to a wider range of disorders is delivery to target tissues. The adoption of delivery technologies, such as conjugates or nanoparticles, has been a game changer for many therapeutic indications, but many others are still awaiting their eureka moment. Here, we cover the variety of methods developed to deliver nucleic acid‐based therapeutics across biological barriers and the model systems used to test them. We discuss important safety considerations and regulatory requirements for synthetic oligonucleotide chemistries and the hurdles for translating laboratory breakthroughs to the clinic. Recent advances in the delivery of nucleic acid‐based therapeutics and in the development of model systems, as well as safety considerations and regulatory requirements for synthetic oligonucleotide chemistries are discussed in this review on oligonucleotide‐based therapeutics.

show abstract

“…Because polycaprolactone (PCL), polylactide (PLA), and poly(lactic-co-glycolic acid) (PLGA) are FDA-approved biocompatible polymers, they are the most used polymers for drug delivery systems (DDS) generation. Other biodegradable polymers such as poly(anhydrides) [14], poly(ortho esters) [15], poly(amides) [16], poly(phosphoesters) [17] and poly(alkyl cyanoacrylates) [18] are great candidates as raw materials to explore nanotechnology. However, their scarce commercial availability hampers their development.…”

Section: Introductionmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.

show abstract

Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft

Cited by 44 publications

References 43 publications

Sonopermeation Enhances Uptake and Therapeutic Effect of Free and Encapsulated Cabazitaxel

Sonopermeation Enhances Uptake and Therapeutic Effect of Free and Encapsulated Cabazitaxel

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

Contact Info

Product

Resources

About